Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers

PHASE2CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

October 31, 2008

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

rFIV vaccine

rF1V vaccine 80 mcg given by intramuscular (IM) injection into the arm on study Days 0, 28, 182

BIOLOGICAL

rF1V vaccine

rF1V 80 mcg vaccine given by intramuscular (IM) injection into the arm on study Days 0, 56, 182

BIOLOGICAL

rF1V vaccine

rF1V 160 mcg vaccine given by intramuscular (IM) injection into the arm on Study Days 0, 28, 182

BIOLOGICAL

rF1V vaccine 160 mcg given on Study Days 0, 56, 182

rF1V 160 mcg vaccine given by Intramuscular (IM) injection into the arm on Study days 0. 56, 182

Trial Locations (9)

15241

Primary Physicians Research, Inc., Pittsburgh

33409

Palm Beach Research, West Palm Beach

40536

University of Kentucky - Dept. of Infectious Disease, Lexington

59802

Infectious Disease Specialists, PC, Missoula

63141

Sundance Clinical Research, St Louis

68134

Meridian clinical Research, LLC, Omaha

85745

Alta Clinical Research, LLC, Tucson

89104

Clinical Research Center of Nevada, Las Vegas

94102

Benchmark Research, San Francisco

All Listed Sponsors
lead

DynPort Vaccine Company LLC, A GDIT Company

INDUSTRY

NCT00332956 - Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers | Biotech Hunter | Biotech Hunter